Unicycive Therapeutics (UNCY) Stock Overview
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
UNCY Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Unicycive Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.70 |
| 52 Week High | US$11.00 |
| 52 Week Low | US$2.83 |
| Beta | 1.87 |
| 1 Month Change | 6.09% |
| 3 Month Change | -21.67% |
| 1 Year Change | 25.37% |
| 3 Year Change | -30.31% |
| 5 Year Change | n/a |
| Change since IPO | -91.97% |
Recent News & Updates
Recent updates
We Think Unicycive Therapeutics (NASDAQ:UNCY) Needs To Drive Business Growth Carefully
Aug 01
We Think Unicycive Therapeutics (NASDAQ:UNCY) Needs To Drive Business Growth Carefully
Apr 01We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely
Dec 11We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
Aug 21Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?
Feb 16We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
Aug 18Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely
Mar 08Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats
Sep 07Unicycive Therapeutics GAAP EPS of -$0.24
Aug 16Unicycive inks licensing deal for kidney disease drug Renazorb in Asia
Jul 18Shareholder Returns
| UNCY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 17.2% | 4.7% | 1.3% |
| 1Y | 25.4% | -6.9% | 16.1% |
Return vs Industry: UNCY exceeded the US Biotechs industry which returned -6.9% over the past year.
Return vs Market: UNCY exceeded the US Market which returned 16.1% over the past year.
Price Volatility
| UNCY volatility | |
|---|---|
| UNCY Average Weekly Movement | 20.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: UNCY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: UNCY's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 23 | Shalabh Gupta | unicycive.com |
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation.
Unicycive Therapeutics, Inc. Fundamentals Summary
| UNCY fundamental statistics | |
|---|---|
| Market cap | US$83.01m |
| Earnings (TTM) | -US$31.50m |
| Revenue (TTM) | n/a |
Is UNCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UNCY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$31.50m |
| Earnings | -US$31.50m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.78 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did UNCY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/18 10:22 |
| End of Day Share Price | 2025/08/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Unicycive Therapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Kumaraguru Raja | Brookline Capital Markets |
| Vamil Divan | Guggenheim Securities, LLC |